ČEŠKOVÁ, Eva. Augmentace antidepresiv atypickými antipsychotiky v léčbě farmakorezistentní deprese (Augmentation of antidepressants with atypical antipsychotics in the treatment of pharmacoresistant depression). Česká a slovenská psychiatrie. Praha: ČLS JEP, vol. 107, No 4, p. 216-219. ISSN 1212-0383. 2011.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Augmentace antidepresiv atypickými antipsychotiky v léčbě farmakorezistentní deprese
Name in Czech Augmentace antidepresiv atypickými antipsychotiky v léčbě farmakorezistentní deprese
Name (in English) Augmentation of antidepressants with atypical antipsychotics in the treatment of pharmacoresistant depression
Authors ČEŠKOVÁ, Eva (203 Czech Republic, guarantor, belonging to the institution).
Edition Česká a slovenská psychiatrie, Praha, ČLS JEP, 2011, 1212-0383.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14740/11:00053001
Organization unit Central European Institute of Technology
Keywords (in Czech) augmentace; antidepresiva; atypická antipsychotika; risperidon; olanzapin; aripiprazol; quetiapin; quetiapin XR
Keywords in English augmentation; antidepressants; atypical antipsychotics; risperidone; olanzapine; aripiprazol; quetiapine; quatiapine XR
Tags ok, rivok
Changed by Changed by: prof. MUDr. Eva Češková, CSc., učo 726. Changed: 7/9/2011 14:49.
Abstract
Augmentace antidepresiv atypickými antipsychotiky je často užívanou strategií v léčbě farmakorezistentní deprese. Je častá v ambulantní léčbě i u hospitalizovaných nemocných. Kontrolované studie byly provedeny s risperidonem, olanzapinem, aripiprazolem a quetiapinem. Quetiapin XR je prvním atypickým antipsychotikem v ČR schváleným jako přídatná léčba depresivních epizod nereagujících dostatečně na monoterapii antidepresiv.
Abstract (in English)
Augmentation of antidepressants with atypical antipsychotics presents an often used strategy in the treatment of pharmacoresistant depression. This strategy is common in both out-patient and in-patient departments. Controlled studies were performed with risperidone, olanzapine, aripiprazol and quetiapine. Quetiapine XR it the first atypical antipsychotic in the Czech Republic proved as adjunctive treatment in depressive episodes non responding adequately to monotherapy with antidepressants.
Links
MSM0021622404, plan (intention)Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.
PrintDisplayed: 28/3/2024 09:08